Carroll Mary A, Vidaeff Alex C, Mele Lisa, Wapner Ronald J, Mercer Brian, Peaceman Alan M, Sorokin Yoram, Dudley Donald J, Spong Catherine Y, Leveno Kenneth J, Harper Margaret, Caritis Steve N, Miodovnik Menachem, Thorp John M, Moawad Atef, O'Sullivan Mary J, Carpenter Marshall W, Rouse Dwight J, Sibai Baha
Department of Obstetrics and Gynecology, University of Texas Houston, Houston, Texas 77030, USA.
Obstet Gynecol. 2008 Jun;111(6):1352-8. doi: 10.1097/AOG.0b013e318173573b.
To compare markers of maternal bone metabolism between women who received a single compared with multiple courses of antenatal corticosteroids.
This is an analysis of serum samples from a previously reported randomized, placebo-controlled, multicenter trial. Women at risk for preterm delivery after an initial course of corticosteroids were randomly assigned to weekly courses of betamethasone (active) or placebo. Serum levels of carboxy terminal propeptide of type I procollagen (PICP) and cross-linked carboxy terminal telopeptide of type I collagen (ICTP) were measured to assess the rate of bone formation and resorption, respectively, at three time points. The placebo group (n=93) was compared with the active group, receiving four or more courses of betamethasone (n=112).
There were significant (P<.001) increases in PICP and ICTP between baseline and delivery in both groups. Cross-linked carboxy terminal telopeptide of type I collagen, but not PICP, was lower with corticosteroid exposure immediately before administration of the fourth study course (P<.001). No significant differences in PICP and ICTP were seen between groups at delivery.
Increasing levels of PICP and ICTP with advancing gestation are consistent with physiologic changes in maternal bone metabolism. Multiple courses of corticosteroids for fetal maturation are not associated with persistent or cumulative effects on maternal bone metabolism as measured by PICP and ICTP.
II.
比较接受单次与多次产前糖皮质激素疗程的女性的母体骨代谢标志物。
这是一项对先前报道的随机、安慰剂对照、多中心试验的血清样本分析。在接受初始糖皮质激素疗程后有早产风险的女性被随机分配接受每周一次的倍他米松(活性药物)或安慰剂疗程。在三个时间点测量血清I型前胶原羧基末端前肽(PICP)和I型胶原交联羧基末端肽(ICTP)水平,分别评估骨形成和骨吸收速率。将安慰剂组(n = 93)与接受四个或更多疗程倍他米松的活性组(n = 112)进行比较。
两组在基线和分娩之间PICP和ICTP均有显著升高(P <.001)。在第四次研究疗程给药前立即暴露于糖皮质激素的情况下,I型胶原交联羧基末端肽(而非PICP)较低(P <.001)。分娩时两组之间PICP和ICTP未见显著差异。
随着孕周增加,PICP和ICTP水平升高与母体骨代谢的生理变化一致。用于胎儿成熟的多次糖皮质激素疗程与通过PICP和ICTP测量的母体骨代谢的持续或累积效应无关。
II级。